Adam Townsend - Apr 21, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Adam Townsend
Stock symbol
APLS
Transactions as of
Apr 21, 2022
Transactions value $
-$166,650
Form type
4
Date filed
7/12/2022, 05:55 PM
Previous filing
Feb 14, 2022
Next filing
Aug 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -1.88K -4.26% $0.00 42.1K Apr 21, 2022 Direct F1
transaction APLS Common Stock Options Exercise $75.5K +5K +11.65% $15.09 47.9K Jul 11, 2022 Direct F2
transaction APLS Common Stock Sale -$242K -5K -10.44% $48.42 42.9K Jul 11, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Other $0 -11.3K -100% $0.00* 0 Apr 21, 2022 Common Stock 11.3K $44.90 Direct F3
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5K -1.33% $0.00 370K Jul 11, 2022 Common Stock 5K $15.09 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This is a scheduled exercise and sale form an established 10b5-1 plan.
F3 This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
F4 This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.